Professional
Added to YB: 2025-06-05
Pitch date: 2025-06-03
CATX [neutral]
Perspective Therapeutics, Inc.
+20.56%
current return
Author Info
Trickle Research is an independent microcap research firm. Visit the website.
Company Info
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
N/A
Pitch Price
$3.21
Price Target
20.50 (+430%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-2.65
EV/Sales
238.33
Sector
Biotechnology
Category
growth
Perspective Therapeutics, Inc. - $CATX
CATX (update): Positive interim safety data from Ph1/2a [212Pb]VMT-α-NET therapy (no DLTs or serious adverse events) at higher dosing levels. 42 patients enrolled with potential correlation between weight & dose. Trading near cash despite promising data. Two other oncology programs advancing. $20.50 PT (12-24mo), 6 allocation.
Read full article (5 min)